Novo Nordisk and the Limits of First-Mover Advantage: Friction and Certainty in the Total Offering
For months, the dominant narrative surrounding GLP-1 drugs for weight loss was based on a simple idea: the first to launch captures the market. Novo Nordisk was that first player. However, the market rarely rewards the story and almost always rewards execution.
CNBC's report of February 25, 2026 cites estimates of around 40% of the market for Novo Nordisk and 60% for Eli Lilly. The body of the report does not specify the geography, measurement period, or whether share is calculated by sales, prescriptions, or volume. Nor does it demonstrate that commercial friction explains that distribution. For a CEO, CFO, or sales leader, the estimate opens a strategic question: beyond the product, what role do access, continuity, and trust play in an offering that makes outcomes credible, repeatable, and defensible?
This is not an article about pharmacology. It is an article about commercial architecture in extremely high-value markets, where customers pay with money, time, and discipline for a very specific promise.
The Myth of the First-Mover Advantage Breaks When the Customer Buys Certainty, Not History
Being first helps to open a category but does not close it. Once a market gains validation, customers stop buying the “discovery” and start purchasing something much colder: perceived certainty. In a product that promises weight loss, the buyer’s mind doesn’t operate on corporate narrative; it operates on practical calculation. The real internal question (without needing to write it out) is whether the result will arrive consistently, with minimal disruptions, and with the lowest total cost of adoption.
The estimate of around 40% reported by CNBC in February raises the limits of being a pioneer, but does not itself identify the causes of the change in share. From a commercial perspective, two forces warrant investigation. They are hypotheses to test, not a proven diagnosis of Novo.
The first force is accelerated commoditization: once there are multiple players with comparable offers, the "I was first" mantra becomes irrelevant. Customers no longer compare against “nothing”; they compare against “another valid alternative.” At this moment, differentiation ceases to be a message and becomes a system: availability, continuity of use, patient experience, payer relations, and a supply chain that doesn’t fail at the precise moment the customer decides to continue or abandon.
The second force is the redistribution of power. In healthcare, the final buyer is not always the sole decision-maker. There are prescribers, insurers, reimbursement systems, and coverage criteria. Each link introduces friction and thus opportunities for a competitor to win with a proposal that reduces steps, uncertainty, or time.
In marketing, this translates into something uncomfortable: positioning is not defended by campaigns alone, but by an experience customers value retaining. If the market is shifting, it is worth investigating which alternatives offer greater value or make switching feel safer or less costly. Movement in share alone does not answer that question.
Friction Can Weaken Market Share When It Rises Faster Than Perceived Value
In high-demand categories, it is tempting to attribute everything to price or advertising. This approach leaves out obstacles that also warrant measurement when the product already has widespread recognition. Accumulated friction is a possible commercial explanation, not a cause we can consider proven in this case.
Friction is not an abstract concept. It encompasses everything that stands between the customer and the outcome: the effort to obtain the product, the continuity of treatment, variability in access, overall financial cost, and the risk of process interruptions. In a weight loss therapy, interruption is not an operational detail; it’s a direct blow to the perception of “this works for me.” If the customer perceives the path as unstable, their willingness to pay diminishes, and their openness to alternatives increases.
The historical estimate of around 40% therefore serves as a starting point for examining execution, not as proof that execution explains the share. For that commercial examination in large-scale healthcare markets, I propose two parallel scorecards:
1. Access Board: How easy it is to start and maintain treatment under real conditions, not in presentations.
2. Trust Board: How robust the perception is that the result will be sustained over time.
Competitors do not need to “be better at everything” to win customers: they may find an opportunity at the stage where most customers are lost. Continuity and experience are candidates that need measuring, not Novo's demonstrated bottleneck. Here lies a critical point for commercial leaders: a strong product does not excuse neglecting a fragile customer journey.
The typical mistake of incumbents is treating this as a communication issue. They invest in explaining, educating, persuading. Meanwhile, the competitor simplifies the path or makes perceived success more probable. In terms of conversion, the market is won by making saying yes the path of least resistance.
GLP-1 Competition Also Plays Out in the Total Offering
CNBC's report addresses Novo's difficulties and Eli Lilly's advances. My commercial reading proposes also examining the defenses around already familiar products. It does not justify concluding that clinical efficacy, safety, price, or innovation no longer matter, or that an access failure alone explains the competition between the two companies.
From this perspective, the unit of analysis expands from the isolated product to the total offering: everything surrounding the product that influences whether the customer adopts, sustains, and recommends it. In regulated sectors, this total offering includes elements that marketing does not fully control but leadership can prioritize.
Understanding this requires observing the dynamics of power. The final customer wants results with minimal sacrifice. The healthcare system wants cost predictability and clear rules. The prescriber wants clinical confidence and a process that does not drain administrative energy. Turning this combination into a seamless experience can strengthen a competitive offering; it does not guarantee any particular share.
When a competitor gains share, these are three commercial levers worth comparing, without assuming that any one of them explains the change on its own:
- Elevating Perceived Certainty: Not only promising but also reducing the feeling of risk around the path.
- Reducing Wait Time: Accelerating start, replenishment, continuity.
- Reducing Effort: Fewer steps, less paperwork, fewer interruptions.
The most important point is that none of these levers are solved by an isolated discount. Competing on price in a high-value category is the shortcut that destroys margins and leaves you without the budget to fix what truly makes you lose.
The lesson I propose from this case is not that the market has stopped evaluating Novo's innovation. It is that any company with a winning product should also examine its value-delivery system. A failure in that system can encourage customers to switch even when the product remains good; determining whether that happened here requires additional evidence.
The Takeaway for Marketing and Pricing Leaders: Market Share is Defended by Making the "Yes" Obvious
From my position in sales and pricing, the takeaway is not “do more branding.” It’s “make the offer so solid that the customer feels reckless abandoning it.” This requires discipline and unpopular decisions.
Firstly, defending share demands identifying where real conversion breaks down. Not in the advertisement, not in declared intent, but at the exact point where adoption stalls: access, continuity, coverage, replenishment. The organization that measures that complete funnel—from prescription to sustained adherence—has a structural advantage.
Secondly, high-value pricing is not sustained by whim. It is sustained when the customer feels they are paying for a probable outcome, not for hope. If the market perceives that the result is less certain due to operational friction, the high price stops seeming "premium" and starts seeming like "risk." When price is perceived as risk, comparison with the competitor becomes immediate.
Thirdly, competitive defense in this type of category resembles engineering more than advertising. It requires financing capabilities not visible in a commercial but felt in use: continuity, support, clarity of processes, and a narrative that promises consistency, not magic.
The 40% estimate published in February is an invitation not to confuse leadership with inertia, not a current measurement by Sustainabl or a causal explanation of the case. First-mover advantage must be defended. Important commercial assets include the ability to deliver results reliably and to reduce friction until customers value retaining the offering. The strategic proposal is to design experiences that reduce friction, strengthen perceived certainty, and increase willingness to pay, without replacing clinical evidence or promising guaranteed outcomes.